Unmet needs in the treatment of autoimmunity: From aspirin to stem cells

Autoimmunity Reviews

Volumn 13, Issue 4-5, 2014, Pages 331-346

  Chang, Christopher ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Biological response modifiers; DMARDS; Glucocorticoids; Janus associated kinase inhibitors; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; BROMELAIN; CHLOROQUINE; COLCHICINE; CURCUMIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GOLD SALT; HYDROXYCHLOROQUINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; TUMOR NECROSIS FACTOR ALPHA; TURMERIC; USTEKINUMAB;

ACTAEA RACEMOSA; ACUPUNCTURE; ANGELICA SINENSIS; ANTIQUITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AYURVEDA; B LYMPHOCYTE; CENTELLA ASIATICA; CHEMOTAXIS; CHINESE MEDICINE; CURCUMA LONGA; DAS28; DRUG EFFICACY; GENOMICS; GINGER; GLYCYRRHIZA; HUMAN; METABOLOMICS; MOLECULAR BIOLOGY; PERSONALIZED MEDICINE; PHAGOCYTOSIS; PROTEOMICS; RESPIRATORY BURST; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL TRANSPLANTATION; TRIPTERYGIUM WILFORDII;

BIOLOGICAL RESPONSE MODIFIERS; DMARDS; GLUCOCORTICOIDS; JANUS ASSOCIATED KINASE INHIBITORS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIRHEUMATIC AGENTS; ASPIRIN; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GENOMICS; HUMANS; STEM CELLS;

EID: 84896318908     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.052     Document Type: Review

References (284)

1. Wang Q., Selmi C., Zhou X., Qiu D., Li Z., Miao Q., et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun 2013, 41:140-145.
2. Ngalamika O., Zhang Y., Yin H., Zhao M., Gershwin M.E., Lu Q. Epigenetics, autoimmunity and hematologic malignancies: a comprehensive review. J Autoimmun 2012, 39:451-465.
3. Gatto M., Zen M., Ghirardello A., Bettio S., Bassi N., Iaccarino L., et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013, 12:523-536.
4. Touitou I. New genetic interpretation of old diseases. Autoimmun Rev 2012, 12:5-9.
5. Miller F.W., Pollard K.M., Parks C.G., Germolec D.R., Leung P.S., Selmi C., et al. Criteria for environmentally associated autoimmune diseases. J Autoimmun 2012, 39:253-258.
6. Miller F.W., Alfredsson L., Costenbader K.H., Kamen D.L., Nelson L.M., Norris J.M., et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun 2012, 39:259-271.
7. Shoenfeld Y., Tincani A., Gershwin M.E. Sex gender and autoimmunity. J Autoimmun 2012, 38:J71-J73.
8. Amur S., Parekh A., Mummaneni P. Sex differences and genomics in autoimmune diseases. J Autoimmun 2012, 38:J254-J265.
9. Bianchi I., Lleo A., Gershwin M.E., Invernizzi P. The X chromosome and immune associated genes. J Autoimmun 2012, 38:J187-J192.
10. Bogdanos D.P., Smyk D.S., Rigopoulou E.I., Mytilinaiou M.G., Heneghan M.A., Selmi C., et al. Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 2012, 38:J156-J169.
11. Chighizola C., Meroni P.L. The role of environmental estrogens and autoimmunity. Autoimmun Rev 2012, 11:A493-A501.
12. Selmi C., Brunetta E., Raimondo M.G., Meroni P.L. The X chromosome and the sex ratio of autoimmunity. Autoimmun Rev 2012, 11:A531-A537.
13. Singh R.P., Waldron R.T., Hahn B.H. Genes, tolerance and systemic autoimmunity. Autoimmun Rev 2012, 11:664-669.
14. Strickland F.M., Hewagama A., Lu Q., Wu A., Hinderer R., Webb R., et al. Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus. J Autoimmun 2012, 38:J135-J143.
15. Moroni L., Bianchi I., Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev 2012, 11:A386-A392.
16. Temajo N.O., Howard N. The viral enterprises in autoimmunity: conversion of target cells into de novo APCs is the presage to autoimmunity. Autoimmun Rev 2012, 11:653-658.
17. Costenbader K.H., Gay S., Alarcon-Riquelme M.E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?. Autoimmun Rev 2012, 11:604-609.
18. Lessard C.J., Ice J.A., Adrianto I., Wiley G.B., Kelly J.A., Gaffney P.M., et al. The genomics of autoimmune disease in the era of genome-wide association studies and beyond. Autoimmun Rev 2012, 11:267-275.
19. Sadovnick A.D. Genetic background of multiple sclerosis. Autoimmun Rev 2012, 11:163-166.
20. Svyryd Y., Hernandez-Molina G., Vargas F., Sanchez-Guerrero J., Segovia D.A., Mutchinick O.M. X chromosome monosomy in primary and overlapping autoimmune diseases. Autoimmun Rev 2012, 11:301-304.
21. Ueki Y., Miyake S., Tominaga Y., Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 1996, 23:230-236.
22. Sharma J.N., Srivastava K.C., Gan E.K. Suppressive effects of eugenol and ginger oil on arthritic rats. Pharmacology 1994, 49:314-318.
23. Amezaga Urruela M., Suarez-Almazor M.E. Acupuncture in the treatment of rheumatic diseases. Curr Rheumatol Rep 2012, 14:589-597.
24. Zhang R.X., Fan A.Y., Zhou A.N., Moudgil K.D., Ma Z.Z., Lee D.Y., et al. Extract of the Chinese herbal formula Huo Luo Xiao Ling Dan inhibited adjuvant arthritis in rats. J Ethnopharmacol 2009, 121:366-371.
25. Thiyagarajan P., Chandrasekaran C.V., Deepak H.B., Agarwal A. Modulation of lipopolysaccharide-induced pro-inflammatory mediators by an extract of Glycyrrhiza glabra and its phytoconstituents. Inflammopharmacology 2011, 19:235-241.
26. Chandrasekaran C.V., Deepak H.B., Thiyagarajan P., Kathiresan S., Sangli G.K., Deepak M., et al. Dual inhibitory effect of Glycyrrhiza glabra (GutGard) on COX and LOX products. Phytomedicine 2011, 18:278-284.
27. Choi J.H., Rho M.C., Lee S.W., Kwon O.E., Park H.R., Kang J.Y., et al. Glabrol, an acyl-coenzyme A: cholesterol acyltransferase inhibitor from licorice roots. J Ethnopharmacol 2007, 110:563-566.
28. Hwang I.K., Lim S.S., Choi K.H., Yoo K.Y., Shin H.K., Kim E.J., et al. Neuroprotective effects of roasted licorice, not raw form, on neuronal injury in gerbil hippocampus after transient forebrain ischemia. Acta Pharmacol Sin 2006, 27:959-965.
29. Kim J.K., Oh S.M., Kwon H.S., Oh Y.S., Lim S.S., Shin H.K. Anti-inflammatory effect of roasted licorice extracts on lipopolysaccharide-induced inflammatory responses in murine macrophages. Biochem Biophys Res Commun 2006, 345:1215-1223.
30. Sylvester J., Liacini A., Li W.Q., Dehnade F., Zafarullah M. Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-kappa B activities. Mol Pharmacol 2001, 59:1196-1205.
31. Tao X.L., Sun Y., Dong Y., Xiao Y.L., Hu D.W., Shi Y.P., et al. A prospective, controlled, double-blind, cross-over study of Tripterygium wilfordii hook F in treatment of rheumatoid arthritis. Chin Med J (Engl) 1989, 102:327-332.
32. Tao X.L. Mechanism of treating rheumatoid arthritis with Tripterygium wilfordii hook. II. Effect on PGE2 secretion. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1989, 11:36-40.
33. Lipsky P.E., Tao X.L. A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 1997, 26:713-723.
34. Schmid D., Gruber M., Woehs F., Prinz S., Etzlstorfer B., Prucker C., et al. Inhibition of inducible nitric oxide synthesis by Cimicifuga racemosa (Actaea racemosa, black cohosh) extracts in LPS-stimulated RAW 264.7 macrophages. J Pharm Pharmacol 2009, 61:1089-1096.
35. Schmid D., Woehs F., Svoboda M., Thalhammer T., Chiba P., Moeslinger T. Aqueous extracts of Cimicifuga racemosa and phenolcarboxylic constituents inhibit production of proinflammatory cytokines in LPS-stimulated human whole blood. Can J Physiol Pharmacol 2009, 87:963-972.
36. Yang C.L., Chik S.C., Li J.C., Cheung B.K., Lau A.S. Identification of the bioactive constituent and its mechanisms of action in mediating the anti-inflammatory effects of black cohosh and related Cimicifuga species on human primary blood macrophages. J Med Chem 2009, 52:6707-6715.
37. Deodhar S.D., Sethi R., Srimal R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980, 71:632-634.
38. Cohen A., Goldman J. Bromelains therapy in rheumatoid arthritis. Pa Med J 1964, 67:27-30.
39. Boiteau P., Ratsimamanga A.R. Asiaticoside extracted from Centella asiatica and its therapeutic uses in cicatrization of experimental and refractory wounds (leprosy, cutaneous tuberculosis and lupus). Therapie 1956, 11:125-149.
40. Paul B.N., Saxena A.K. Depletion of tumor necrosis factor-alpha in mice by Nyctanthes arbor-tristis. J Ethnopharmacol 1997, 56:153-158.
41. Kumar I.V., Paul B.N., Asthana R., Saxena A., Mehrotra S., Rajan G. Swertia chirayita mediated modulation of interleukin-1beta, interleukin-6, interleukin-10, interferon-gamma, and tumor necrosis factor-alpha in arthritic mice. Immunopharmacol Immunotoxicol 2003, 25:573-583.
42. Hosseinzadeh H., Younesi H.M. Antinociceptive and anti-inflammatory effects of Crocus sativus L. stigma and petal extracts in mice. BMC Pharmacol 2002, 2:7.
43. Agarwal R.B., Rangari V.D. Phytochemical investigation and evaluation of anti-inflammatory and anti-arthritic activities of essential oil of Strobilanthus ixiocephala Benth. Indian J Exp Biol 2003, 41:890-894.
44. Chamundeeswari D., Vasantha J., Gopalakrishnan S., Sukumar E. Free radical scavenging activity of the alcoholic extract of Trewia polycarpa roots in arthritic rats. J Ethnopharmacol 2003, 88:51-56.
45. Kim M.S., Yi J.M., Kim S.H., Hong S.H., Kim H.M. Madimadi, Korean folk medicine, blocks TNF-alpha, IL-1beta, and IL-8 production by activated human immune cells. Cytokine 2004, 25:179-186.
46. Yu F., Yu F., Li R., Wang R. Inhibitory effects of the Gentiana macrophylla (Gentianaceae) extract on rheumatoid arthritis of rats. J Ethnopharmacol 2004, 95:77-81.
47. Koch E. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med 2001, 67:489-500.
48. Tong Y., Zhang X., Zhao W., Zhang Y., Lang J., Shi Y., et al. Anti-angiogenic effects of Shiraiachrome A, a compound isolated from a Chinese folk medicine used to treat rheumatoid arthritis. Eur J Pharmacol 2004, 494:101-109.
49. Hartung E.F. History of the use of colchicum and related medicaments in gout; with suggestions for further research. Ann Rheum Dis 1954, 13:190-200.
50. Dixon W.E., Malden W. Colchicine with special reference to its mode of action and effect on bone-marrow. J Physiol 1908, 37:50-76.
51. Peters J.J. A cytological study of mitosis in the cornea of Triturus viridescens during recovery after colchicine treatment. J Exp Zool 1946, 103:33-59.
52. Wang R.Y., Morasco R., Henry G.C., Hoffman R.S., Goldfrank L.R. Antidotal efficacy of glutamate and aspartate for colchicine toxicity. Vet Hum Toxicol 1997, 39:207-210.
53. Finkelstein Y., Aks S.E., Hutson J.R., Juurlink D.N., Nguyen P., Dubnov-Raz G., et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 2010, 48:407-414.
54. Kean W.F., Forestier F., Kassam Y., Buchanan W.W., Rooney P.J. The history of gold therapy in rheumatoid disease. Semin Arthritis Rheum 1985, 14:180-186.
55. Forestier J. Copper and gold salts in rheumatoid arthritis. Ann Rheum Dis 1949, 8:132-134.
56. De Wall S.L., Painter C., Stone J.D., Bandaranayake R., Wiley D.C., Mitchison T.J., et al. Noble metals strip peptides from class II MHC proteins. Nat Chem Biol 2006, 2:197-201.
57. Bondeson J., Sundler R. Auranofin inhibits the induction of interleukin 1 beta and tumor necrosis factor alpha mRNA in macrophages. Biochem Pharmacol 1995, 50:1753-1759.
58. Clark P., Tugwell P., Bennet K., Bombardier C., Shea B., Wells G., et al. Injectable gold for rheumatoid arthritis. Cochrane Database Syst Rev 2000, CD000520.
59. Paladini I., Menchini U., Mencucci R. Corneal chrysiasis: in vivo confocal microscopy analysis. Eur J Ophthalmol 2010, 20:776-779.
60. Langan S.M., Harrison C., Wright G.D. Unusual and memorable. Chrysiasis secondary to sodium aurothiomalate treatment. Ann Rheum Dis 1999, 58:68.
61. Smith R.W., Cawley M.I. Chrysiasis. Br J Rheumatol 1997, 36:3-5.
62. Fleming C.J., Salisbury E.L., Kirwan P., Painter D.M., Barnetson R.S. Chrysiasis after low-dose gold and UV light exposure. J Am Acad Dermatol 1996, 34:349-351.
63. Bonet M., Olive A., Maymo J., Cucurull J., Nogueroles A., Arnal C. Chrysiasis in rheumatoid arthritis. Clin Rheumatol 1990, 9:254-255.
64. Pelachyk J.M., Bergfeld W.F., McMahon J.T. Chrysiasis following gold therapy for rheumatoid arthritis: ultrastructural analysis with x-ray energy spectroscopy. J Cutan Pathol 1984, 11:491-494.
65. Beckett V.L., Doyle J.A., Hadley G.A., Spear K.L. Chrysiasis resulting from gold therapy in rheumatoid arthritis: identification of gold by x-ray microanalysis. Mayo Clin Proc 1982, 57:773-777.
66. Jeffery D., Biggs D.F., Percy J.S., Russell A.S. Quantitation of gold in skin in chrysiasis. J Rheumatol 1975, 2:28-35.
67. Luijten R.K., Fritsch-Stork R.D., Bijlsma J.W., Derksen R.H. The use of glucocorticoids in systemic lupus erythematosus. After 60years still more an art than science. Autoimmun Rev 2013, 12:617-628.
68. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013, [in press]. 10.1136/annrheumdis-2013-204573.
69. Bondeson J. The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol 1997, 29:127-150.
70. Goldstein G. A case of dermatomyositis treated with 6-mercaptopurine and azathioprine. Med J Aust 1965, 1:715-717.
71. Eridani S., Taglioretti D., Tiso R. Clinical trial of azathioprine, a new antileukaemic compound. Panminerva Med 1965, 7:275-281.
72. Patel A.A., Swerlick R.A., McCall C.O. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006, 55:369-389.
73. Remuzzi G., Lesti M., Gotti E., Ganeva M., Dimitrov B.D., Ene-Iordache B., et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004, 364:503-512.
74. Abu-Shakra M., Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001, 10:152-153.
75. Olszewska M., Kolacinska-Strasz Z., Sulej J., Labecka H., Cwikla J., Natorska U., et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol 2007, 8:85-92.
76. Cosnes J., Bourrier A., Laharie D., Nahon S., Bouhnik Y., Carbonnel F., et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013, 145:758-765. [e2; quiz e14-5].
77. Bourrier A., Seksik P., Cosnes J. Is there still a room for azathioprine monotherapy in inflammatory bowel disease?. Curr Drug Targets 2013, 14:1471-1479.
78. Cosnes J., Seksik P. Early azathioprine in Crohn's disease. Inflamm Bowel Dis 2013, 19:674-675.
79. Camus M., Seksik P., Bourrier A., Nion-Larmurier I., Sokol H., Baumer P., et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol 2013, 11:389-394.
80. Richman D.P., Agius M.A. Treatment of autoimmune myasthenia gravis. Neurology 2003, 61:1652-1661.
81. McGovern D.P., Jewell D.P. Risks and benefits of azathioprine therapy. Gut 2005, 54:1055-1059.
82. Suarez-Almazor M.E., Spooner C., Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000, CD001461.
83. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996, 5(Suppl. 1):S4-S10.
84. Hurst N.P., French J.K., Gorjatschko L., Betts W.H. Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release. J Rheumatol 1988, 15:23-27.
85. Niermeijer J.M., Eurelings M., van der Linden M.W., Lokhorst H.M., Franssen H., Fischer K., et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology 2007, 69:50-59.
86. Shanafelt T.D., Lin T., Geyer S.M., Zent C.S., Leung N., Kabat B., et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007, 109:2291-2298.
87. Lindman H., Astrom G., Ahlgren J., Villman K., Blomqvist C., Nygren P., et al. Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. Acta Oncol 2007, 46:165-171.
88. Linden H.M., Haskell C.M., Green S.J., Osborne C.K., Sledge G.W., Shapiro C.L., et al. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stages I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol 2007, 25:656-661.
89. Benson D.M., Elder P.J., Lin T.S., Blum W., Penza S., Avalos B., et al. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res 2007, 31:1069-1075.
90. Kay N.E., Geyer S.M., Call T.G., Shanafelt T.D., Zent C.S., Jelinek D.F., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007, 109:405-411.
91. Borchers A.T., Leibushor N., Naguwa S.M., Cheema G.S., Shoenfeld Y., Gershwin M.E. Lupus nephritis: a critical review. Autoimmun Rev 2012, 12:174-194.
92. Diaz-Lagares C., Croca S., Sangle S., Vital E.M., Catapano F., Martinez-Berriotxoa A., et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012, 11:357-364.
93. Luce J.K., Simons J.A. Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis. Med Pediatr Oncol 1988, 16:372-374.
94. Shepherd J.D., Pringle L.E., Barnett M.J., Klingemann H.G., Reece D.E., Phillips G.L. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991, 9:2016-2020.
95. Matsuda S., Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000, 47:119-125.
96. Starzl T.E., Iwatsuki S., Malatack J.J., Zitelli B.J., Gartner J.C., Hakala T.R., et al. Liver and kidney transplantation in children receiving cyclosporin A and steroids. J Pediatr 1982, 100:681-686.
97. Starzl T.E., Klintmalm G.B., Porter K.A., Iwatsuki S., Schroter G.P. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med 1981, 305:266-269.
98. Starzl T.E., Iwatsuki S., Klintmalm G., Schroter G.P., Weil R., Koep L.J., et al. Liver transplantation, 1980, with particular reference to cyclosporin-A. Transplant Proc 1981, 13:281-285.
99. Yousuf S., Atif F., Kesherwani V., Agrawal S.K. Neuroprotective effects of tacrolimus (FK-506) and cyclosporin (CsA) in oxidative injury. Brain Behav 2011, 1:87-94.
100. Walshe J.M. Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956, 21:487-495.
101. Camp A.V. Penicillamine in the treatment of rheumatoid arthritis. Proc R Soc Med 1977, 70:67-69.
102. Steen V.D., Medsger T.A., Rodnan G.P. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982, 97:652-659.
103. Masson M.J., Teranishi M., Shenton J.M., Uetrecht J.P. Investigation of the involvement of macrophages and T cells in D-penicillamine-induced autoimmunity in the Brown Norway rat. J Immunotoxicol 2004, 1:79-93.
104. Seguin B., Masson M.J., Uetrecht J. D-penicillamine-induced autoimmunity in the Brown Norway rat: role for both T and non-T splenocytes in adoptive transfer of tolerance. Chem Res Toxicol 2004, 17:1299-1302.
105. Masson M.J., Uetrecht J.P. Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chem Res Toxicol 2004, 17:82-94.
106. Li J., Uetrecht J.P. D-penicillamine-induced autoimmunity: relationship to macrophage activation. Chem Res Toxicol 2009, 22:1526-1533.
107. Li J., Mannargudi B., Uetrecht J.P. Covalent binding of penicillamine to macrophages: implications for penicillamine-induced autoimmunity. Chem Res Toxicol 2009, 22:1277-1284.
108. Fishel B., Tishler M., Caspi D., Yaron M. Fatal aplastic anaemia and liver toxicity caused by D-penicillamine treatment of rheumatoid arthritis. Ann Rheum Dis 1989, 48:609-610.
109. Cherwinski H.M., McCarley D., Schatzman R., Devens B., Ransom J.T. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995, 272:460-468.
110. Alcantara A.C., Leite C.A., Leite A.C., Sidrim J.J., Silva F.S., Rocha F.A. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis. J Rheumatol 2013, [in press]. 10.3899/jrheum.130294.
111. De Leon A., Sanchez G., Contreras R. Renal infarct in rheumatic heart disease. Anatomoclinical study of 210 cases. Arch Inst Cardiol Mex 1968, 38:542-550.
112. Kloppenburg M., Terwiel J.P., Mallee C., Breedveld F.C., Dijkmans B.A. Minocycline in active rheumatoid arthritis. A placebo-controlled trial. Ann N Y Acad Sci 1994, 732:422-423.
113. Kloppenburg M., Breedveld F.C., Terwiel J.P., Mallee C., Dijkmans B.A. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1994, 37:629-636.
114. Breedveld F.C., Dijkmans B.A., Mattie H. Minocycline treatment for rheumatoid arthritis: an open dose finding study. J Rheumatol 1990, 17:43-46.
115. Golstein P.E., Deviere J., Cremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 1997, 92:143-146.
116. Malcolm A., Heap T.R., Eckstein R.P., Lunzer M.R. Minocycline-induced liver injury. Am J Gastroenterol 1996, 91:1641-1643.
117. Dwyer C.M., Cuddihy A.M., Kerr R.E., Chapman R.S., Allam B.F. Skin pigmentation due to minocycline treatment of facial dermatoses. Br J Dermatol 1993, 129:158-162.
118. Guillon J.M., Joly P., Autran B., Denis M., Akoun G., Debre P., et al. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Intern Med 1992, 117:476-481.
119. Kuzell W.C., Gardner G.M. Salicylazosulfapyridine (salazopyrin or azopyrin) in rheumatoid arthritis and experimental polyarthritis. Calif Med 1950, 73:476-480.
120. Baron J.H., Connell A.M., Lennard-Jones J.E., Jones F.A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962, 1:1094-1096.
121. McGirt L.Y., Vasagar K., Gober L.M., Saini S.S., Beck L.A. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006, 142:1337-1342.
122. Gardner M.D., Bargen J.A. Hemolytic anemia secondary to salicylazosulfapyridine therapy. JAMA 1964, 190:71-72.
123. Cantarini L., Tinazzi I., Biasi D., Fioravanti A., Galeazzi M. Sulfasalazine-induced immune thrombocytopenia. Postgrad Med J 2007, 83:e1.
124. Detroy R.W., Freer S.N., Fennell D.I. Relationship between the biosynthesis of virus-like particles and mycophenolic acid in Penicillium stoloniferum and Penicillium brevicompactum. Can J Microbiol 1973, 19:1459-1462.
125. Ransom J.T. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995, 17:681-684.
126. Moore R.A., Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006, 8:R182.
127. D'Cruz D.P., Khamashta M.A., Hughes G.R. Systemic lupus erythematosus. Lancet 2007, 369:587-596.
128. Liberal R., Grant C.R., Mieli-Vergani G., Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun 2013, 41:126-139.
129. Bertino J.R., Donohue D.R., Gabrio B.W., Silber R., Alenty A., Meyer M., et al. Increased level of dihydrofolic reductase in leucocytes of patients treated with amethopterin. Nature 1962, 193:140-142.
130. Meyer L.M., Miller F.R., Rowen M.J., Bock G., Rutzky J. Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid). Acta Haematol 1950, 4:157-167.
131. Antikajian G., Wright L.T., Plummer J.I., Weintraub S. The effect of triethylene melamine, aureomycin, and some 4-amino derivatives of folic acid on tissues in vitro. J Natl Cancer Inst 1951, 12:269-274.
132. Wright J.C., Prigot A., Wright B., Weintraub S., Wright L.T. An evaluation of folic acid antagonists in adults with neoplastic diseases: a study of 93 patients with incurable neoplasms. J Natl Med Assoc 1951, 43:211-240.
133. Hertz R., Li M.C., Spencer D.B. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956, 93:361-366.
134. Cambrosio A., Keating P. Between fact and technique: the beginnings of hybridoma technology. J Hist Biol 1992, 25:175-230.
135. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
136. Lonberg N., Huszar D. Human antibodies from transgenic mice. Int Rev Immunol 1995, 13:65-93.
137. Carmen S., Jermutus L. Concepts in antibody phage display. Brief Funct Genomic Proteomic 2002, 1:189-203.
138. Kolb W.P., Granger G.A. Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. Proc Natl Acad Sci U S A 1968, 61:1250-1255.
139. Ruddle N.H., Waksman B.H. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. 3. Analysis of mechanism. J Exp Med 1968, 128:1267-1279.
140. Ruddle N.H., Waksman B.H. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. II. Correlation of the in vitro response with skin reactivity. J Exp Med 1968, 128:1255-1265.
141. Ruddle N.H., Waksman B.H. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon. J Exp Med 1968, 128:1237-1254.
142. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72:3666-3670.
143. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
144. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003, 10:45-65.
145. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 2002, 296:1634-1635.
146. Kant S., Swat W., Zhang S., Zhang Z.Y., Neel B.G., Flavell R.A., et al. TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev 2011, 25:2069-2078.
147. Gaur U., Aggarwal B.B. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003, 66:1403-1408.
148. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993, 30:1443-1453.
149. Peppel K., Crawford D., Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991, 174:1483-1489.
150. Peppel K., Poltorak A., Melhado I., Jirik F., Beutler B. Expression of a TNF inhibitor in transgenic mice. J Immunol 1993, 151:5699-5703.
151. Kolls J., Peppel K., Silva M., Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1994, 91:215-219.
152. Keystone E.C., Genovese M.C., Klareskog L., Hsia E.C., Hall S.T., Miranda P.C., et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009, 68:789-796.
153. Keystone E., Heijde D., Mason D., Landewe R., Vollenhoven R.V., Combe B., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008, 58:3319-3329.
154. Atzeni F., Sarzi-Puttini P., Botsios C., Carletto A., Cipriani P., Favalli E.G., et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012, 12:225-229.
155. Atzeni F., Talotta R., Salaffi F., Cassinotti A., Varisco V., Battellino M., et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013, 12:703-708.
156. Efe C. Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship?. Autoimmun Rev 2013, 12:337-339.
157. Jiang Y., Genant H.K., Watt I., Cobby M., Bresnihan B., Aitchison R., et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000, 43:1001-1009.
158. Fleischmann R. Anakinra in the treatment of rheumatic disease. Expert Rev Clin Immunol 2006, 2:331-340.
159. Fleischmann R.M., Tesser J., Schiff M.H., Schechtman J., Burmester G.R., Bennett R., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1006-1012.
160. Kuemmerle-Deschner J.B., Hachulla E., Cartwright R., Hawkins P.N., Tran T.A., Bader-Meunier B., et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011, 70:2095-2102.
161. Caorsi R., Federici S., Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012, 12:81-86.
162. Doria A., Zen M., Bettio S., Gatto M., Bassi N., Nalotto L., et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev 2012, 12:22-30.
163. Chang C. The pathogenesis of neonatal autoimmune and autoinflammatory diseases: a comprehensive review. J Autoimmun 2013, 41:100-110.
164. Genovese M.C., McKay J.D., Nasonov E.L., Mysler E.F., da Silva N.A., Alecock E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008, 58:2968-2980.
165. Cambridge G., Perry H.C., Nogueira L., Serre G., Parsons H.M., De La Torre I., et al. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun 2013, [in press]. 10.1016/j.jaut.2013.12.002.
166. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
167. Edwards J.C., Leandro M.J., Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004, 30:393-403. [viii].
168. Keystone E., Emery P., Peterfy C.G., Tak P.P., Cohen S., Genovese M.C., et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009, 68:216-221.
169. Buch M.H., Rubbert-Roth A., Ferraccioli G. To switch or not to switch after a poor response to a TNFalpha blocker? It is not only a matter of ACR20 OR ACR50. Autoimmun Rev 2012, 11:558-562.
170. Genovese M.C., Kaine J.L., Lowenstein M.B., Del Giudice J., Baldassare A., Schechtman J., et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008, 58:2652-2661.
171. Atzeni F., Sarzi-Puttini P., Mutti A., Bugatti S., Cavagna L., Caporali R. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 2013, 12:1115-1117.
172. Caporali R., Bugatti S., Cavagna L., Antivalle M., Sarzi-Puttini P. Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?. Autoimmun Rev 2014, 13:49-53.
173. Cutolo M., Nadler S.G. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 2013, 12:758-767.
174. Sandborn W.J., Colombel J.F., Sands B.E., Rutgeerts P., Targan S.R., Panaccione R., et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012, 143:62-69. [e4].
175. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
176. Wofsy D., Hillson J.L., Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012, 64:3660-3665.
177. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
178. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
179. Weber J., Keam S.J. Ustekinumab. BioDrugs 2009, 23:53-61.
180. Mariette X., Seror R., Quartuccio L., Baron G., Salvin S., Fabris M., et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2013, [in press]. 10.1136/annrheumdis-2013-203991.
181. Belimumab. No tangible efficacy but a risk of immunosuppression. Prescrire Int 2013, 22:149.
182. Petri M.A., van Vollenhoven R.F., Buyon J., Levy R.A., Navarra S.V., Cervera R., et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013, 65:2143-2153.
183. Hahn B.H. Belimumab for systemic lupus erythematosus. N Engl J Med 2013, 368:1528-1535.
184. Parodis I., Axelsson M., Gunnarsson I. Belimumab for systemic lupus erythematosus: a practice-based view. Lupus 2013, 22:372-380.
185. Mosak J., Furie R. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy. Lupus 2013, 22:361-371.
186. Dooley M.A., Houssiau F., Aranow C., D'Cruz D.P., Askanase A., Roth D.A., et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013, 22:63-72.
187. Wallace D.J., Navarra S., Petri M.A., Gallacher A., Thomas M., Furie R., et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013, 22:144-154.
188. Berrih-Aknin S., Ragheb S., Le Panse R., Lisak R.P. Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun Rev 2013, 12:885-893.
189. Vyas D., O'Dell K.M., Bandy J.L., Boyce E.G. Tofacitinib: the first Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2013, 47:1524-1531.
190. Berhan A. Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies. BMC Musculoskelet Disord 2013, 14:332.
191. Dowty M.E., Jesson M.I., Ghosh S., Lee J., Meyer D.M., Krishnaswami S., et al. Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis. J Pharmacol Exp Ther 2014, 348:165-173.
192. Yamaoka K., Tanaka Y. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opin Pharmacother 2014, 15:103-113.
193. He Y., Wong A.Y., Chan E.W., Lau W.C., Man K.K., Chui C.S., et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord 2013, 14:298.
194. Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis. Ann Intern Med 2013, 159:1-26.
195. Kremer J., Li Z.G., Hall S., Fleischmann R., Genovese M., Martin-Mola E., et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013, 159:253-261.
196. Kim J.W., Choi I.A., Lee E.Y., Song Y.W., Lee E.B. Tofacitinib prevents radiographic progression in rheumatoid arthritis. J Korean Med Sci 2013, 28:1134-1138.
197. Rakieh C., Conaghan P.G. Tofacitinib for treatment of rheumatoid arthritis. Adv Ther 2013, 30:713-726.
198. Scott L.J. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs 2013, 73:857-874.
199. Gremese E., Ferraccioli G. Tofacitinib for rheumatoid arthritis. Lancet 2013, 381:1812.
200. Bannwarth B., Kostine M., Poursac N. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 2013, 9:753-761.
201. Cutolo M. The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Disord 2013, 5:3-11.
202. van der Heijde D., Tanaka Y., Fleischmann R., Keystone E., Kremer J., Zerbini C., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013, 65:559-570.
203. Tofacitinib (Xeljanz) for rheumatoid arthritis. Med Lett Drugs Ther 2013, 55:1-3.
204. Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 2012, 69:2120.
205. Tanaka Y., Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol 2013, 23:415-424.
206. de Lartigue J. Tofacitinib for the treatment of moderate to severe rheumatoid arthritis. Drugs Today (Barc) 2012, 48:533-543.
207. van Vollenhoven R.F., Fleischmann R., Cohen S., Lee E.B., Garcia Meijide J.A., Wagner S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012, 367:508-519.
208. Fleischmann R., Kremer J., Cush J., Schulze-Koops H., Connell C.A., Bradley J.D., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012, 367:495-507.
209. Zerbini C.A., Lomonte A.B. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2012, 8:319-331.
210. Tanaka Y., Suzuki M., Nakamura H., Toyoizumi S., Zwillich S.H. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011, 63:1150-1158.
211. Bushmakin A.G., Mamolo C., Cappelleri J.C., Stewart M. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat 2013, [in press]. 10.3109/09546634.2013.861891.
212. Ortiz-Ibanez K., Alsina M.M., Munoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr 2013, 104:304-310.
213. Strober B., Buonanno M., Clark J.D., Kawabata T., Tan H., Wolk R., et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013, 169:992-999.
214. Paul S., Roblin X. Tofacitinib in active ulcerative colitis. N Engl J Med 2012, 367:1959-1960. [author reply 60-1].
215. Peyrin-Biroulet L., Danese S. Tofacitinib: janus bifrons in ulcerative colitis treatment. Gastroenterology 2013, 144:1136-1138.
216. Sandborn W.J., Ghosh S., Panes J., Vranic I., Su C., Rousell S., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012, 367:616-624.
217. Seo G.S. The efficacy and safety of a tofacitinib in the treatment of active ulcerative colitis. Korean J Gastroenterol 2013, 61:354-355.
218. Vuitton L., Koch S., Peyrin-Biroulet L. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. Curr Drug Targets 2013, 14:1385-1391.
219. Vafadari R., Quaedackers M.E., Kho M.M., Mol W.M., Chan G., Weimar W., et al. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. Transplantation 2012, 94:465-472.
220. Vincenti F., Tedesco Silva H., Busque S., O'Connell P., Friedewald J., Cibrik D., et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 2012, 12:2446-2456.
221. Wojciechowski D., Vincenti F. Tofacitinib in kidney transplantation. Expert Opin Investig Drugs 2013, 22:1193-1199.
222. Maiga M., Lun S., Guo H., Winglee K., Ammerman N.C., Bishai W.R. Risk of tuberculosis reactivation with tofacitinib (CP-690550). J Infect Dis 2012, 205:1705-1708.
223. Papp K.A., Menter A., Strober B., Langley R.G., Buonanno M., Wolk R., et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012, 167:668-677.
224. Ports W.C., Khan S., Lan S., Lamba M., Bolduc C., Bissonnette R., et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013, 169:137-145.
225. Jin Q., Moritoki Y., Lleo A., Tsuneyama K., Invernizzi P., Moritoki H., et al. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology 2012, 55:1495-1506.
226. Takahashi T., Miura T., Nakamura J., Yamada S., Yanagi M., Matsuda Y., et al. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology 2012, 55:846-855.
227. Tsuda M., Moritoki Y., Lian Z.X., Zhang W., Yoshida K., Wakabayashi K., et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012, 55:512-521.
228. Lleo A., Liao J., Invernizzi P., Zhao M., Bernuzzi F., Ma L., et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 2012, 55:153-160.
229. Dhirapong A., Yang G.X., Nadler S., Zhang W., Tsuneyama K., Leung P., et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 2013, 57:708-715.
230. Cui Y., Sheng Y., Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 2013, 41:25-33.
231. Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun 2013, 41:1-5.
232. Luo Y., Wang Y., Wang Q., Xiao R., Lu Q. Systemic sclerosis: genetics and epigenetics. J Autoimmun 2013, 41:161-167.
233. Pillai S. Rethinking mechanisms of autoimmune pathogenesis. J Autoimmun 2013, 45:97-103.
234. Singh A.K., Mahlios J., Mignot E. Genetic association, seasonal infections and autoimmune basis of narcolepsy. J Autoimmun 2013, 43:26-31.
235. Fabris M., Quartuccio L., Lombardi S., Saracco M., Atzeni F., Carletto A., et al. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 2012, 11:315-320.
236. Stefan M., Zhang W., Concepcion E., Yi Z., Tomer Y. DNA methylation profiles in type 1 diabetes twins point to strong epigenetic effects on etiology. J Autoimmun 2013, [in press]. 10.1016/j.jaut.2013.10.001.
237. Coit P., Jeffries M., Altorok N., Dozmorov M.G., Koelsch K.A., Wren J.D., et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun 2013, 43:78-84.
238. Katoh H., Zheng P., Liu Y. FOXP3: genetic and epigenetic implications for autoimmunity. J Autoimmun 2013, 41:72-78.
239. Zhang P., Zhao M., Liang G., Yin G., Huang D., Su F., et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J Autoimmun 2013, 41:17-24.
240. Thabet Y., Le Dantec C., Ghedira I., Devauchelle V., Cornec D., Pers J.O., et al. Epigenetic dysregulation in salivary glands from patients with primary Sjogren's syndrome may be ascribed to infiltrating B cells. J Autoimmun 2013, 41:175-181.
241. Wang Z., Zheng Y., Hou C., Yang L., Li X., Lin J., et al. DNA methylation impairs TLR9 induced Foxp3 expression by attenuating IRF-7 binding activity in fulminant type 1 diabetes. J Autoimmun 2013, 41:50-59.
242. Zhang Y., Zhao M., Sawalha A.H., Richardson B., Lu Q. Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun 2013, 41:92-99.
243. Svendsen A.J., Hjelmborg J.V., Kyvik K.O., Houen G., Nielsen C., Skytthe A., et al. The impact of genes on the occurrence of autoantibodies in rheumatoid arthritis. A study on disease discordant twin pairs. J Autoimmun 2013, 41:120-125.
244. Tanaka A., Takikawa H. Geoepidemiology of primary sclerosing cholangitis: a critical review. J Autoimmun 2013, 46:35-40.
245. Singh R.P., Massachi I., Manickavel S., Singh S., Rao N.P., Hasan S., et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev 2013, 12:1160-1165.
246. Iborra M., Bernuzzi F., Invernizzi P., Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev 2012, 11:305-314.
247. Thamilarasan M., Koczan D., Hecker M., Paap B., Zettl U.K. MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. Autoimmun Rev 2012, 11:174-179.
248. Ando Y., Yang G.X., Kenny T.P., Kawata K., Zhang W., Huang W., et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. J Autoimmun 2013, 41:111-119.
249. De Iudicibus S., Lucafo M., Martelossi S., Pierobon C., Ventura A., Decorti G. MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. World J Gastroenterol 2013, 19:7947-7954.
250. Cipriani P., Carubbi F., Liakouli V., Marrelli A., Perricone C., Perricone R., et al. Stem cells in autoimmune diseases: implications for pathogenesis and future trends in therapy. Autoimmun Rev 2013, 12:709-716.
251. Antonelli A., Ferrari S.M., Giuggioli D., Ferrannini E., Ferri C., Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2013, 13(3):272-280.
252. Dooms H. Interleukin-7: fuel for the autoimmune attack. J Autoimmun 2013, 45:40-48.
253. Dimitroulas T., Nikas S.N., Trontzas P., Kitas G.D. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev 2013, 12:958-966.
254. Mayer C.T., Tian L., Hesse C., Kuhl A.A., Swallow M., Kruse F., et al. Anti-CD4 treatment inhibits autoimmunity in scurfy mice through the attenuation of co-stimulatory signals. J Autoimmun 2013, [in press]. 10.1016/j.jaut.2013.08.010.
255. Cuadrado M.J., Sciascia S., Bosch X., Khamashta M.A., Ramos-Casals M. Is it time for biosimilars in autoimmune diseases?. Autoimmun Rev 2013, 12:954-957.
256. Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014, 13:24-30.
257. Leardini G., Rigon C. The impact of the profile of biologics on treatment costs. Autoimmun Rev 2013, 12:842-847.
258. Epis O.M., Giacomelli L., Deidda S., Bruschi E. Tight control applied to the biological therapy of rheumatoid arthritis. Autoimmun Rev 2013, 12:839-841.
259. Agmon-Levin N., Mosca M., Petri M., Shoenfeld Y. Systemic lupus erythematosus one disease or many?. Autoimmun Rev 2012, 11:593-595.
260. Amador-Patarroyo M.J., Arbelaez J.G., Mantilla R.D., Rodriguez-Rodriguez A., Cardenas-Roldan J., Pineda-Tamayo R., et al. Sjogren's syndrome at the crossroad of polyautoimmunity. J Autoimmun 2012, 39:199-205.
261. Anaya J.M. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev 2012, 11:781-784.
262. Tobon G.J., Pers J.O., Canas C.A., Rojas-Villarraga A., Youinou P., Anaya J.M. Are autoimmune diseases predictable?. Autoimmun Rev 2012, 11:259-266.
263. Atzeni F., Benucci M., Salli S., Bongiovanni S., Boccassini L., Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 2013, 12:575-579.
264. Yuan Y., Kasar S., Underbayev C., Vollenweider D., Salerno E., Kotenko S.V., et al. Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus. Mol Immunol 2012, 52:61-70.
265. Pan W., Zhu S., Yuan M., Cui H., Wang L., Luo X., et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 2010, 184:6773-6781.
266. Garchow B.G., Bartulos Encinas O., Leung Y.T., Tsao P.Y., Eisenberg R.A., Caricchio R., et al. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med 2011, 3:605-615.
267. Zhu S., Pan W., Song X., Liu Y., Shao X., Tang Y., et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat Med 2012, 18:1077-1086.
268. Fan W., Liang D., Tang Y., Qu B., Cui H., Luo X., et al. Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 2012, 64:3715-3725.
269. Niederer F., Trenkmann M., Ospelt C., Karouzakis E., Neidhart M., Stanczyk J., et al. Down-regulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum 2012, 64:1771-1779.
270. Yang J., Lu Y.W., Lu M.M., Leng R.X., Pan H.F., Ye D.Q. MicroRNA-101, mitogen-activated protein kinases and mitogen-activated protein kinases phosphatase-1 in systemic lupus erythematosus. Lupus 2013, 22:115-120.
271. Kawano S., Nakamachi Y. miR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70(Suppl. 1):88-91.
272. Zhao X., Tang Y., Qu B., Cui H., Wang S., Wang L., et al. MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum 2010, 62:3425-3435.
273. Kim S.W., Ramasamy K., Bouamar H., Lin A.P., Jiang D., Aguiar R.C. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappa B pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A 2012, 109:7865-7870.
274. Zhao S., Wang Y., Liang Y., Zhao M., Long H., Ding S., et al. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 2011, 63:1376-1386.
275. Luo X., Yang W., Ye D.Q., Cui H., Zhang Y., Hirankarn N., et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 2011, 7:e1002128.
276. Pauley K.M., Satoh M., Chan A.L., Bubb M.R., Reeves W.H., Chan E.K. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 2008, 10:R101.
277. Niimoto T., Nakasa T., Ishikawa M., Okuhara A., Izumi B., Deie M., et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 2010, 11:209.
278. Lu J., Kwan B.C., Lai F.M., Tam L.S., Li E.K., Chow K.M., et al. Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. Nephrology (Carlton) 2012, 17:346-351.
279. Wang G., Tam L.S., Kwan B.C., Li E.K., Chow K.M., Luk C.C., et al. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol 2012, 31:435-440.
280. Xu W.D., Lu M.M., Pan H.F., Ye D.Q. Association of microRNA-146a with autoimmune diseases. Inflammation 2012, 35:1525-1529.
281. Kurowska-Stolarska M., Alivernini S., Ballantine L.E., Asquith D.L., Millar N.L., Gilchrist D.S., et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A 2011, 108:11193-11198.
282. Stanczyk J., Ospelt C., Karouzakis E., Filer A., Raza K., Kolling C., et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011, 63:373-381.
283. Lu M.C., Lai N.S., Chen H.C., Yu H.C., Huang K.Y., Tung C.H., et al. Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis. Clin Exp Immunol 2013, 171:91-99.
284. Pandis I., Ospelt C., Karagianni N., Denis M.C., Reczko M., Camps C., et al. Identification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model. Ann Rheum Dis 2012, 71:1716-1723.